In contrast, in the genetic context of mutant TP53, FOSB expression correlated with a larger tumor size, a higher TNM stage, a lower therapeutic response, and a more negative therapeutic outcome, implying potential pro-tumor effects of FOSB in NSCLC harboring mutant TP53 (Fig. 2C). Here, FOSB is linked to non-small cell lung carcinoma.